Covaxin: Indigenous Vaccine for COVID-19
Covaxin is India's first vaccine candidate to have gone into human clinical trials. It is developed by Bharat Biotech and has been approved by the Drug Controller General of India (DCGI) for phase I and II human clinical trials.
- The SARS-CoV-2 strain was isolated in National Institute of Virology (NIV), Pune and transferred to Bharat Biotech. They developed Covaxin as an “inactivated” vaccine — one made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate. Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Harnessing Bioeconomy for India’s Development Leap
- 2 India’s Energy Security: A Strategic Reset
- 3 Reimagining Urban India: Towards Integrated, Sustainable and Future-Ready Infrastructure
- 4 Resilient Supply Chains: A Pillar of India’s Economic Security
- 5 Digital Safety for Children: Rights, Risks, and Regulatory Gaps
- 6 Green Technology: India's Carbon Credit Ambiguity and the Road to Net Zero
- 7 Passive Euthanasia in India: Ethical Concerns
- 8 Rights of Gig Workers in India
- 9 Building a Robust Innovation Ecosystem in India: From Scale to Depth
- 10 From Tokenism to Transformation: Strengthening Women’s Political Voice in India
